We noted you are experiencing viewing problems
- 
        
        Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
 - 
        
        Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. - 
        
        No luck yet? More tips for troubleshooting viewing issues
 - 
        
        Contact HST Support access@hstalks.com
 
- 
        Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
 - 
        For additional help, please don't hesitate to contact HST support access@hstalks.com
 
We hope you have enjoyed this limited-length demo
                    
                    This is a limited length demo talk; you may
                    
                      login or
                    
                    review methods of
                    obtaining more access.
                  
                
                
              Printable Handouts
Navigable Slide Index
- Introduction
 - Biological activity of Ab is a critical component
 - B cell-directed immunotherapies
 - Antigen expression during B cell development
 - B lymphocyte targets for immunotherapy
 - CD20 immunotherapy for lymphoma
 - CD20-directed immunotherapies (1)
 - CD20-directed immunotherapies (2)
 - CD20 immunotherapy for lymphoma - rituximab
 - Key Ab properties for Ab-mediated immunotherapy
 - Antibody structure and classes
 - Affinity and avidity
 - Immunogenicity (1)
 - Immunogenicity (2)
 - Half-life
 - Ab effects on B cell function
 - CD20: function, structure and expression
 - CD20 hypothetical structure on B lymphocytes
 - CD20 complex-mediated Ca2+ conductance
 - Ab binding to CD20 inhibits decrease in [Ca2+]i
 - CD20-deficient B cell [Ca2+]i responses
 - Membrane spanning-4A gene family
 - MS4a expression by mouse tissues
 - Antibody effects on B cell function
 - Antibody dependant cellular cytotoxicity
 - Mouse anti-mouse CD20 monoclonal antibodies
 - MB20 mAb depletion of B cells in vivo
 - CD20 mAb effects on bone marrow B cells
 - CD20 mAb depletes blood B cells
 - CD20 mAb depletes spleen B cells in vivo
 - CD20 mAb eliminates majority of mature B cells
 - B cell depletion after CD20 mAb treatment
 - The peritoneal cavity provides a protective niche
 - Inflammation abrogates the protective niche
 - FcR expression is required for B cell depletion
 - B cell depletion by CD20 requires monocytes
 - CD20 antibodies induce ADCC
 - Complement dependent cytotoxicity (CDC)
 - B cell depletion does not require C'/ T/ NK cells
 - Mouse survival following A20 lymphoma inoculation
 - CD20 treatment eliminates most of mature B cells
 - Non-responsiveness and resistance to CD20 mAb
 - CD20 immunotherapy for autoimmunity
 - S.c CD20 mAb administration is effective
 - B cell depletion in TSK/+ mice by CD20 mAb
 - B cell depletion reduces skin fibrosis
 - CD20-directed immuotherapies
 - Mechanistic studies of CD20 mAb immunotherapy
 
Topics Covered
- Antibody targeting of B-cell malignancies and autoimmunity
 - CD20 antibody immunotherapy
 - CD20 structure and function
 - Antibody-dependent cellular cytotoxicity
 - Complement-dependent cytotoxicity
 - Mouse models of CD20 immunotherapy
 - Lymphoma immunotherapy
 - Immunotherapy for autoimmunity
 
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Tedder, T. (2007, October 1). CD20 antibodies in the targeting of B-cell malignancies and autoimmunity [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 4, 2025, from https://doi.org/10.69645/GIRG6026.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Thomas Tedder has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
 
CD20 antibodies in the targeting of B-cell malignancies and autoimmunity
A selection of talks on Immunology & Inflammation
        Hide